Author(s): Dhananjay Sangle, Amit Naik, Amol Ghorpade, Vikram Ghatkar, Suvarna Ghuge, Dipti Ingle, Rishikesh Ingle

Email(s): sangle_dhananjay@rediffmail.com

DOI: Not Available

Address: Dr. Dhananjay Sangle1*, Dr.Amit Naik1, Dr. Amol Ghorpade2, Dr. Vikram Ghatkar2, Dr. Suvarna Ghuge2, Dr. Dipti Ingle2, Dr. Rishikesh Ingle2
1Assistant Professor, University Department of Interpathy Research and Technology (UDIRT), Maharashtra University of Health Sciences (MUHS), Nashik.
2M.Sc. Pharmaceutical Medicine, University Department of Interpathy Research and Technology (UDIRT), Maharashtra University of Health Sciences (MUHS), Nashik.
*Corresponding Author

Published In:   Volume - 6,      Issue - 9,     Year - 2013


ABSTRACT:
Objective: The primary objective of study was to perform a cost effectiveness analysis study between Tab. Atenolol (50mg OD) and Tab. Amlodipine (5mg OD) in treatment of essential hypertension as a mono-therapy. The secondary objective was to evaluate and compare the tolerability of study medications. Method: This observational, prospective, comparative, parallel group, phase IV study was conducted at District Civil Hospital over a period of 8 weeks. Total 300 patients fulfilling the inclusion criteria i.e. having essential hypertension and receiving monotherapy of either Amlodipine or Atenolol were selected for the study after written informed consent. There were 150 patients each in Atenolol group (50mg OD) and Amlodipine group (5mg OD). Unit costs of atenolol and amlodipine were applied to the daily dosages of individual patients to calculate the total costs and average costs per patient in each treatment group on an intent-to-treat basis. Efficacy rates were used to calculate the average treatment cost per unit (10 mm of Hg) reduction in Mean Arterial Pressure (MAP). The MAP was calculated at baseline visit and at final visit (at the end of 8 weeks). Result: Tab. Amlodipine (5mg) OD required less cost i.e. Rs.3.43/pt. as compared to Tab.Atenolol (50mg) OD i.e Rs.5.05/pt. for the reduction of MAP by one unit (i.e.10 mm Hg). There was no statistically significant difference between average MAP reduction in Amlodipine monotherapy (17.49 mm Hg) Vs Atenolol monotherapy (16.61 mm Hg) .Although not statistically significant, Amlodipine treatment resulted in a higher ADRs (23.33%) vs. Atenolol (18.66%) Conclusion: This study concludes that Amlodipine monotherapy is more cost effective compared with an Atenolol monotherapy.


Cite this article:
Dhananjay Sangle, Amit Naik, Amol Ghorpade, Vikram Ghatkar, Suvarna Ghuge, Dipti Ingle, Rishikesh Ingle. Cost Effectiveness Analysis Study between Atenolol and Amlodipine in Essential Hypertension. Research J. Pharm. and Tech. 6(9): September 2013; Page 1001-1003.


Recomonded Articles:

Author(s): Deependra Jain, Nishiprakash Jain, SK Jain, Nitin Jonwal, Shashank Mishra, Deepak Bhatt, Soham Shukla

DOI: Not Available         Access: Open Access Read More

Author(s): Dhananjay Sangle, Amit Naik, Amol Ghorpade, Vikram Ghatkar, Suvarna Ghuge, Dipti Ingle, Rishikesh Ingle

DOI: Not Available         Access: Open Access Read More

Author(s): Jayawardhani V., Rajesh A. Kamtane, Ashok K. Kulkarni

DOI: Not Available         Access: Open Access Read More

Author(s): Suganya M, Yadavi Soondron, Mahadeva Rao US.

DOI: Not Available         Access: Open Access Read More

Author(s): Sandeep Goyal, V.K. Bansal, Dhruba Sankar Goswami, Suresh Kumar

DOI: Not Available         Access: Open Access Read More

Author(s): N Narasimharao, P Srinivasa Babu1, V Sai Kishore, TE Gopala krishna murthy

DOI:         Access: Open Access Read More

Author(s): Gayathri. V, J. Sharmila, N. Navyatha, P. Kalyani, Silvya Grace. B, Balaiah. S, T. Vinay Kumar, Hare Krishna Roy

DOI: 10.5958/0974-360X.2019.00647.4         Access: Open Access Read More

Author(s): Raghunathan Nivetha, Balasubramanian Arul, Ramalingam Kothai

DOI: 10.5958/0974-360X.2019.00788.1         Access: Open Access Read More

Author(s): Karthikeyan Murthykumar, Dhanraj

DOI: 10.5958/0974-360X.2016.00111.6         Access: Open Access Read More

Author(s): Selman M. Selman

DOI: 10.5958/0974-360X.2018.00696.0         Access: Open Access Read More

Author(s): Din Amalia Widyaningrum, Wenny Putri Nilamsari, Wardah Rahmatul Islamiyah, Dewi Wara Shinta

DOI: 10.5958/0974-360X.2020.00103.1         Access: Closed Access Read More

Author(s): Chinnu Scaria, Ananthu Satheesh, Pooja Prabhakar, Juno J. Joel, Shishir Kumar

DOI: 10.5958/0974-360X.2019.00585.7         Access: Open Access Read More

Author(s): Diksha Sharma, Dinesh Kumar Mehta, Karun Bhatti, Rina Das, Ram Mohan Chidurala

DOI: 10.5958/0974-360X.2020.00532.6         Access: Closed Access Read More

Author(s): Abdullahi Rabiu Abubakar, Nordin Bin Simbak, Mainul Haque

DOI: Not Available         Access: Open Access Read More

Author(s): Anitha Elango, K. Punnagai, Darling Chellathai, Arul Amutha Elizebeth

DOI: 10.5958/0974-360X.2020.00118.3         Access: Closed Access Read More

Author(s): Bhavika D. Satone, Atul A. Deshmukh, Vaishali R. Undale

DOI: 10.5958/0974-360X.2020.00372.8         Access: Closed Access Read More

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags